P70S6K/Akt inhibitor M2698

Drug Overview

P70S6K/Akt inhibitor M2698 (also known by its developmental code MSC2363318A) is an investigational, orally bioavailable, small-molecule dual-targeted kinase inhibitor. It is specifically engineered to simultaneously inhibit two critical components of the PI3K/Akt/mTOR signaling pathway: p70S6 kinase (p70S6K) and Akt (Protein Kinase B).

In the clinical landscape of March 2026, M2698 represents a strategic evolution in the treatment of “pathway-addicted” solid tumors. The PI3K/Akt/mTOR pathway is one of the most frequently dysregulated systems in human cancer, driving uncontrolled cell growth, survival, and resistance to therapy. While many earlier drugs targeted only one part of this “circuit,” M2698 is designed to provide a “double-hit.” By blocking both p70S6K and Akt, the drug aims to prevent the “feedback loops” that often allow cancer cells to bypass single-target inhibitors. Developed by Merck KGaA (EMD Serono), M2698 is being evaluated for its ability to cross the blood-brain barrier, making it a high-potential candidate for treating cancers that have spread to the central nervous system.

• Generic Name: P70S6K/Akt inhibitor M2698.
• Code Name: M2698, MSC2363318A.
• Drug Class: Dual p70S6K and Akt Inhibitor; PI3K/Akt/mTOR Pathway Inhibitor.
• Mechanism: Competitive inhibition of ATP binding to p70S6K and Akt1/3 isoforms.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, M2698 is not FDA-approved. It has completed Phase 1 dose-escalation studies and is currently in Phase 2 clinical trials for specific molecularly-defined cancers.

What Is It and How Does It Work? (Mechanism of Action)

M2698 works by “short-circuiting” the internal communication lines that cancer cells use to grow and resist death.

1. The PI3K/Akt/mTOR Signaling Cascade

In many breast, lung, and gastric cancers, the PI3K pathway is stuck in the “on” position. This acts like a green light for the cell to divide constantly.

• Akt’s Role: Akt is a “master switch” that prevents the cell from dying (anti-apoptosis) and promotes glucose metabolism.
• p70S6K’s Role: This kinase is a downstream “effector” that tells the cell’s machinery to start building new proteins for growth.

2. Overcoming Feedback Loops

A major problem with older “mTOR-only” inhibitors is that when you block mTOR, the cell senses the drop in energy and sends a signal to “turn up” Akt as a backup. This is called a pro-survival feedback loop.

• The Dual Blockade: Because M2698 blocks both the downstream target (p70S6K) and the upstream activator (Akt), it prevents the cell from switching to its backup power source.
• Irreversible Growth Arrest: This comprehensive shutdown makes it much harder for the tumor to develop resistance, forcing the cell into G1-phase cell cycle arrest.

3. Crossing the Blood-Brain Barrier

Many kinase inhibitors are too large to enter the brain. M2698 was specifically screened for its ability to penetrate the Blood-Brain Barrier (BBB). This allows the drug to reach therapeutic levels in the brain, targeting brain metastases that are shielded from other types of chemotherapy.

Clinical Indications and Research Status (2026)

In 2026, M2698 is being prioritized for cancers with specific genetic mutations in the PI3K pathway:

• Advanced Breast Cancer (HER2+ and PIK3CA Mutant): This is the most advanced area of research. M2698 is being studied in combination with trastuzumab (Herceptin) to overcome resistance in patients who have progressed on standard anti-HER2 therapies.
• Brain Metastases: Due to its high BBB penetration, M2698 is being evaluated in patients whose breast or lung cancer has spread to the brain.
• Solid Tumors with PIK3CA or PTEN Alterations: Investigated in “basket trials” for any tumor harboring mutations that over-activate the Akt pathway.
• Combination with Tamoxifen: Research in 2025 suggested that M2698 can “re-sensitize” hormone-receptor-positive breast cancer to endocrine therapy by blocking the escape pathways.

Dosage and Administration Protocols

As an investigational agent, M2698 dosing is strictly managed to balance pathway inhibition with the body’s normal metabolic functions.

Clinical Efficacy and Research Results (2024–2026)

Recent data from Phase 1b expansion cohorts have provided significant insights into M2698’s potential:

• Pharmacodynamic Target Hit: 2025 results showed that at the 200 mg dose level, M2698 achieved a >90% reduction in the phosphorylation of S6RP (a marker of p70S6K activity) in tumor biopsies.
• Brain Response: In a small 2026 sub-study of patients with HER2+ brain metastases, M2698 in combination with lapatinib demonstrated a 30% intracranial response rate, a notable result for this difficult-to-treat population.
• Safety Threshold: Research has confirmed that the drug’s dual action is more potent than single-target inhibitors but requires careful monitoring of blood sugar levels.

Safety Profile and Side Effects

The side effects of M2698 are primarily “on-target” toxicities related to the inhibition of the insulin-signaling pathway.

1. Hyperglycemia (High Blood Sugar)

Because the Akt pathway is involved in how cells process insulin, blocking it can lead to high blood sugar.

• Symptoms: Increased thirst, frequent urination, and fatigue.
• Management: Patients often require oral glucose-lowering medications (like metformin) while on M2698.

2. Gastrointestinal (GI) Effects

• Symptoms: Nausea, vomiting, and diarrhea are common, occurring in approximately 40% of patients.
• Management: Usually managed with standard anti-diarrheal and anti-emetic care.

3. General Fatigue and Rash

• Significant tiredness has been reported.
• A “maculopapular” rash (small red bumps) can occur, which is a common class effect of PI3K/Akt pathway inhibitors.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, M2698 is being used to study “Stem Cell Quiescence.” Researchers are investigating if inhibiting the Akt pathway can prevent Cancer Stem Cells from “waking up” and causing a recurrence years after treatment. In 2026, there is also intense focus on “Immune-Metabolism,” where scientists are looking at how M2698-induced changes in cellular glucose use can make the tumor microenvironment more hospitable for T-cells, potentially paving the way for combinations with immunotherapy.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Molecular Profiling: Mandatory testing to confirm PIK3CA mutation or PTEN loss.
• Baseline Glucose: A hemoglobin A1c (HbA1c) and fasting blood glucose test must be performed.

“Do’s and Don’ts” List:

• DO monitor your blood sugar at home if you have a history of pre-diabetes; M2698 can cause sudden spikes.
• DO report any “new-onset blurry vision” or “extreme thirst” immediately.
• DON’T take the medication with a high-fat meal, as this can change how much of the drug crosses into your brain.
• DON’T ignore persistent diarrhea; early management is key to staying on the effective dose of the medication.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. M2698 (MSC2363318A) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis, molecular markers, and clinical trial eligibility.